Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABT-751 · 4 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| ABT-751 | DRUG | - |
Inclusion Criteria * Stage IIIB or IV non-small cell lung cancer. * Recurrent tumor following treatment with paclitaxel or docetaxel. * Able to tolerate normal activities of daily living. * Adequate bone marrow, kidney and liver function. Exclusion Criteria * Pregnant or breast feeding. * Anti-tu...
Top 20 of 92 competitors
ABT-751 is an investigational small molecule being studied in oncology for the treatment of breast cancer, non-small cell lung cancer, renal cell cancer, and colorectal cancer. It is being developed by Abbott Laboratories and is currently in Phase 2 clinical development.
ABT-751 is being developed by Abbott Laboratories, a company traded on the New York Stock Exchange under the ticker symbol ABT. The drug is an investigational small molecule in Phase 2 clinical development for multiple cancer indications.
ABT-751 is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Clinical trials for the drug have been completed, and it is being studied for breast cancer, non-small cell lung cancer, renal cell cancer, and colorectal cancer.
ABT-751 has completed four Phase 2 clinical trials: NCT00063102 for recurrent breast cancer, NCT00073112 for renal cell cancer, NCT00073138 for colorectal cancer, and NCT00073151 for non-small cell lung cancer. These trials were conducted in the United States and Canada.
ABT-751 is the primary name for this investigational drug. No alternative names have been reported for this compound. It is being developed by Abbott Laboratories for the treatment of several types of cancer.